<DOC>
	<DOCNO>NCT01215539</DOCNO>
	<brief_summary>The purpose study determine whether panitumumab combination capecitabine/oxaliplatin effective first-line treatment wild-type k-ras , metastatic colorectal cancer patient .</brief_summary>
	<brief_title>Study Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description>This single-arm trial previously untreated , wild-type k-ras metastatic colorectal cancer patient receive therapy combination panitumumab capecitabine oxaliplatin . During treatment period 6 cycle , subject evidence complete response , partial response stable disease continue receive combination chemotherapy panitumumab disease progression , unacceptable toxicity withdrawal consent . Those patient disease stabilization appropriate chemotherapy may continue panitumumab alone . Patients disease progression discontinue chemotherapy panitumumab follow every 3 month last drug administration death . Tumor response assess accord RECIST criterion ( investigator 's read scan ) , every 6 week week 18 every 3 month thereafter , disease progression . Disease progression also evaluate radiographically time clinical suspicion progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Ability comprehend sign inform consent 2 . Aged 18 year 3 . Histologically cytologicallyconfirmed metastatic adenocarcinoma colon and/or rectum 4 . Measurable disease accord RECIST criterion 5 . Eastern Cooperative Oncology Group ( ECOG ) status 02 6 . Nonmutated kras gene ( kras status assess DNA sequence codon 12 13 ) 7 . Haematologic function : ANC &gt; 1.5 x 109/L , Leucocyte count &gt; 3000/mm3 , Haemoglobin &gt; 10g/ L , PLT &gt; 100 x 109/ L 8 . Renal function : serum creatinine ≤1.5xUNL creatinine clearance &gt; 50ml/min 9 . Hepatic function : Total bilirubin ≤ 1.5 time upper normal limit ( UNL ) ASAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastases ALAT ≤ 2.5xUNL absence liver metastasis , ≤5xUNL presence liver metastases 10 . Metabolic function : Magnesium ≥ low limit normal . Calcium ≥ low limit normal . 1 . Central nervous system metastases 2 . Prior therapy metastatic disease 3 . Adjuvant chemotherapy last 6 month 4 . Prior antiEGFR therapy treatment EGFR tyrosine kinase inhibitor 5 . Prior radiotherapy within 30 day enrollment 6 . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) &lt; =1 year enrollment 7 . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . 8 . Inflammatory bowel disease chronic diarrhea 9 . Dihydropyrimidine deficiency 10 . Positive test HIV infection , hepatitis C infection , chronic active hepatitis B infection 11 . Any kind disorder compromise ability patient give inform consent 12 . Any investigational agent within 30 day prior initiation study 13 . Any surgical procedure within 28 day prior initiation study 14 . Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . 15 . Female subject childbearing age positive pregnancy test screen initiation study treatment . 16 . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>